• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.

作者信息

DiNicolantonio James J, Barroso Jorge, McCarty Mark

机构信息

Department of Preventive Cardiology, Mid America Heart Insitute, Kansas, Missouri, USA

Clinica Libre de Adicciones, Tijuana, Baja California, Mexico.

出版信息

Open Heart. 2020 Sep;7(2). doi: 10.1136/openhrt-2020-001350.

DOI:10.1136/openhrt-2020-001350
PMID:32895293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7476419/
Abstract
摘要

相似文献

1
Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.伊维菌素可能是一种对晚期新冠肺炎有临床实用价值的抗炎药。
Open Heart. 2020 Sep;7(2). doi: 10.1136/openhrt-2020-001350.
2
Is the type of diabetes treatment relevant to outcome of COVID-19?糖尿病治疗类型与新型冠状病毒肺炎的预后有关吗？
J Diabetes. 2020 Jul;12(7):486-487. doi: 10.1111/1753-0407.13047.
3
Statins in coronavirus outbreak: It's time for experimental and clinical studies.冠状病毒爆发中的他汀类药物：是时候进行实验和临床研究了。
Pharmacol Res. 2020 Jun;156:104803. doi: 10.1016/j.phrs.2020.104803. Epub 2020 Apr 11.
4
Statin therapy and SAR-COV-2: an available and potential therapy?他汀类药物治疗与新型冠状病毒2：一种可行且有潜力的治疗方法？
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):333-334. doi: 10.1093/ehjcvp/pvaa050.
5
Audio Interview: Tocilizumab and Covid-19.音频访谈：托珠单抗与新冠病毒
N Engl J Med. 2020 Oct 22;383(17):e114. doi: 10.1056/NEJMe2032051.
6
Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.新型冠状病毒感染非危重症患者的深静脉血栓形成。
Thromb Res. 2020 Aug;192:27-28. doi: 10.1016/j.thromres.2020.05.015. Epub 2020 May 14.
7
Sofosbuvir for COVID-19 infection: A potential candidate.索磷布韦用于治疗新型冠状病毒肺炎感染：一个潜在的候选药物。
Indian J Pharmacol. 2020 May-Jun;52(3):232-233. doi: 10.4103/ijp.IJP_675_20. Epub 2020 Aug 4.
8
[Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].[严重急性呼吸综合征冠状病毒2（SARS-CoV-2）：我们应该针对病毒、细胞还是疾病？]
Virologie (Montrouge). 2020 Jun 1;24(3):135-141. doi: 10.1684/vir.2020.0843.
9
Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.抗炎治疗可能会改善新冠肺炎的临床症状。
Ann Rheum Dis. 2020 Sep;79(9):1253-1254. doi: 10.1136/annrheumdis-2020-217562. Epub 2020 Apr 28.
10
Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.伊维菌素、抗病毒特性和 COVID-19：一种可能的新作用机制。
Naunyn Schmiedebergs Arch Pharmacol. 2020 Jul;393(7):1153-1156. doi: 10.1007/s00210-020-01902-5. Epub 2020 May 27.

引用本文的文献

1
Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients.伊维菌素和硝唑尼特治疗墨西哥新冠门诊及住院患者的临床经验
Cureus. 2024 Nov 26;16(11):e74513. doi: 10.7759/cureus.74513. eCollection 2024 Nov.
2
Unveiling the Potential of Silymarin, , and towards Cardiotoxicity via Modulating Antioxidant Activity, Inflammation, and Apoptosis in Rats.通过调节大鼠的抗氧化活性、炎症和细胞凋亡揭示水飞蓟素、[此处原文缺失部分内容]及[此处原文缺失部分内容]对心脏毒性的潜在作用。
Life (Basel). 2024 Oct 11;14(10):1289. doi: 10.3390/life14101289.
3
ACV with/without IVM: a new talk on intestinal CDX2 and muscular CD34 and Cyclin D1 during infection.阿昔洛韦联合/不联合伊维菌素：关于感染期间肠道CDX2、肌肉CD34和细胞周期蛋白D1的新探讨。
Helminthologia. 2024 Jul 16;61(2):124-141. doi: 10.2478/helm-2024-0013. eCollection 2024 Jun.
4
Development and validation of ivermectin quantification method in volumetric absorptive microsampling using liquid chromatography-tandem mass spectrometry.使用液相色谱-串联质谱法在体积吸收微采样中进行伊维菌素定量方法的开发与验证
Heliyon. 2024 Apr 15;10(8):e29606. doi: 10.1016/j.heliyon.2024.e29606. eCollection 2024 Apr 30.
5
What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms.有哪些当前的抗 COVID-19 药物？从传统到智能的分子机制。
Virol J. 2023 Oct 24;20(1):241. doi: 10.1186/s12985-023-02210-z.
6
SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）：一篇强调其进化与治疗方法的最新综述
Vaccines (Basel). 2022 Dec 14;10(12):2145. doi: 10.3390/vaccines10122145.
7
Ivermectin Attenuates CCl-Induced Liver Fibrosis in Mice by Suppressing Hepatic Stellate Cell Activation.伊维菌素通过抑制肝星状细胞活化减轻 CCl 诱导的小鼠肝纤维化。
Int J Mol Sci. 2022 Dec 16;23(24):16043. doi: 10.3390/ijms232416043.
8
Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic.伊维菌素：新冠疫情期间的一个争议焦点。
Life (Basel). 2022 Sep 6;12(9):1384. doi: 10.3390/life12091384.
9
Ivermectin-Induced Acute Psychosis in Patients Infected With COVID-19 Pneumonia.感染新冠病毒肺炎患者中伊维菌素诱发的急性精神病
Cureus. 2022 Jun 21;14(6):e26141. doi: 10.7759/cureus.26141. eCollection 2022 Jun.
10
The use of Ivermectin for the treatment of COVID-19: Panacea or enigma?伊维菌素用于治疗新冠肺炎：万灵药还是谜团？
Clin Epidemiol Glob Health. 2022 Jul-Aug;16:101074. doi: 10.1016/j.cegh.2022.101074. Epub 2022 Jun 8.

本文引用的文献

1
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study.使用伊维菌素与 COVID-19 住院患者的死亡率降低相关：COVID-19 中的伊维菌素研究。
Chest. 2021 Jan;159(1):85-92. doi: 10.1016/j.chest.2020.10.009. Epub 2020 Oct 13.
2
Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?细胞外 HMGB1：严重肺部炎症（包括 COVID-19）的治疗靶点？
Mol Med. 2020 May 7;26(1):42. doi: 10.1186/s10020-020-00172-4.
3
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.伊维菌素单独批准的剂量不是治疗 COVID-19 的理想剂量。
Clin Pharmacol Ther. 2020 Oct;108(4):762-765. doi: 10.1002/cpt.1889. Epub 2020 Jun 7.
4
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
5
Topical ivermectin improves allergic skin inflammation.局部使用伊维菌素可改善过敏性皮肤炎症。
Allergy. 2017 Aug;72(8):1212-1221. doi: 10.1111/all.13118. Epub 2017 Feb 6.
6
Anti-inflammatory effects of ivermectin in mouse model of allergic asthma.伊维菌素对过敏性哮喘小鼠模型的抗炎作用。
Inflamm Res. 2011 Jun;60(6):589-96. doi: 10.1007/s00011-011-0307-8. Epub 2011 Jan 29.
7
Phylogeny and metabolic scaling in mammals.哺乳动物的系统发育和代谢缩放。
Ecology. 2010 Sep;91(9):2783-93. doi: 10.1890/09-0817.1.
8
Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway.阿维菌素通过下调核转录因子κB和丝裂原活化蛋白激酶激活途径发挥抗炎作用。
Fundam Clin Pharmacol. 2009 Aug;23(4):449-55. doi: 10.1111/j.1472-8206.2009.00684.x. Epub 2009 May 6.
9
Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages.伊维菌素对脂多糖刺激的RAW 264.7巨噬细胞中一氧化氮和前列腺素E2产生的抑制作用。
Int Immunopharmacol. 2009 Mar;9(3):354-9. doi: 10.1016/j.intimp.2008.12.016. Epub 2009 Jan 23.
10
Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice.伊维菌素可抑制脂多糖诱导的炎性细胞因子生成，并提高脂多糖诱导的小鼠存活率。
Inflamm Res. 2008 Nov;57(11):524-9. doi: 10.1007/s00011-008-8007-8.